Biomarker-based Alzheimer's Disease Cohort Study (BASIC)

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This study adopts a prospective cohort design, constructing a single-center cohort by recruiting patients with Alzheimer's disease (AD) who are positive for AD biomarkers. First, the investigators aim to establish a cohort of AD patients with positive biomarkers, thereby reserving suitable patient resources for future AD-related clinical trials. Second, based on the established cohort, the investigators will explore the associations between AD-related biomarkers and clinical manifestations among the elderly population in China, and identify potential risk factors influencing the progression of AD. Third, according to the identified risk factors for AD progression, the investigators will construct a risk early warning model for the progression rate of AD based on biomarkers, in order to achieve early identification and precise prevention and control of the progression risk of AD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Healthy Volunteers: f
View:

• (1) Patients aged 40 years or older;

• (2) Visiting Xuanwu Hospital, Capital Medical University;

• (3) Meeting the core clinical diagnostic criteria for Alzheimer's disease (AD) - related mild cognitive impairment or probable AD according to the NIA-AA (2011);

• (4) Amyloid positivity confirmed by amyloid PET or cerebrospinal fluid biomarker tests;

• (5) Providing informed consent.

Locations
Other Locations
China
Xuanwu Hospital of Capital Medical University
RECRUITING
Beijing
Contact Information
Primary
Liyang Liu
liuliyang@xwhosp.org
17888828131
Time Frame
Start Date: 2019-01-01
Estimated Completion Date: 2050-12-31
Participants
Target number of participants: 2835
Treatments
Patients diagnosed with Alzheimer's disease with AD biomarker positivity.
This cohort recruits patients diagnosed with Alzheimer's disease based on clinical symptoms, neuroimaging features and AD biomarkers. Biomarker positivity is necessary for inclusion.
Related Therapeutic Areas
Sponsors
Leads: Xuanwu Hospital, Beijing

This content was sourced from clinicaltrials.gov